Thesis (Ph. D.)--University of Missouri--Columbia, 1996. / Typescript. Vita. Includes bibliographical references (leaves: 106-117). Also available on the Internet.

Thesis (M.S.)--University of Michigan, 1979.

Literature review part of this thesis focuses on the diabetes mellitus diagnosis and its negative effects on mental health and social relationships of diagnosed patients in form of diabetes distress. The research part investigates change of diabetes distress measured by Diabetes distress scale (DDS) and glycated haemoglobin HbA1c in the beginning, at the end and 6 months after the end of the group educational course. The group consisted of 66 Czech people diagnosed with type 2 diabetes (mean age 62 years, SD = 9,77; median = 63,5). Increased diabetes distress (DDS value ≥ 2) in the 1st measurement of DDS was reported by 15 people out of 52 (29%). There was a significant decrease in HbA1c from the beginning to the end of the course (χ2 (2) = 22.5; p <0,001) and this low level was maintained even after 6 months after the course. A non-significant reduction in diabetes distress between 1st and 2nd measurement was observed in 45 subjects (W = 509; p = 0,098). A statistically significant reduction in diabetes distress was observed between the 1st and 2nd DDS measurement only in those 23 subjects (χ2 (2) = 9,50; p = 0,002) who also participated in 3rd DDS measurement - further research in this area would be appropriate. In our sample, no significant difference was found between the sexes, DDS and HbA1c,...

Introdução - Pacientes portadores de diabetes tipo 1 que manifestam comportamentos de risco para transtornos alimentares (TA) possuem grandes chances de complicações microvasculares e macrovasculares e maiores taxas de mortalidade. Objetivo Avaliar a freqüência de comportamento de risco para TA em adolescentes e adultos portadores de diabetes tipo 1 bem como sua relação com variáveis socioeconômicas, nutricionais, relacionadas ao diabetes e satisfação corporal. Metodologia: Foram aplicados: Teste de Investigação Bulímica de Edinburgh (BITE), Teste de Atitudes Alimentares (EAT), Escala de Compulsão Alimentar Periódica (ECAP) e Escala de Silhuetas de Stunkard, além da mensuração de peso, estatura e cálculo do IMC. Foram verificadas associações ou diferenças estatísticas por meio dos testes de Qui-Quadrado e T-Student e Regressão Logística para identificar fatores que influenciaram o risco da doença. Resultados: Um total de 58,7% dos pacientes apresentaram escore positivo em algum dos testes utilizados para risco de TA. Houve diferença significante entre os grupos com e sem risco para TA com relação ao IMC (p=0,009), gênero (p=0,001), omissão de insulina (p=0,003), uso de insulina NPH (p=0,006), ausência do uso da insulina Glargina (p=0,021), ausência do uso da técnica de contagem de carboidratos (p=0,019), controle da glicemia (p=0,049) e insatisfação corporal (p=0,001). Conclusão: Portadores de diabetes tipo 1 apresentaram grande freqüência de comportamentos de risco para o TA, o que requer atenção e cautela dos profissionais de saúde. / Introduction - Patients suffers of type 1 diabetes that reveal risk behavior for eating disorders (ED) have more chances of micro and macro vascular complications and a high mortality level. Objective Evaluate the frequency of risk behavior for ED in teenagers and adults suffers of type 1 diabetes as well as its relation to the socially economical variable, nutritional variable, related to diabetes and body satisfaction. Methodology: There was applied: The Bulimic Inventory Test of Edinburgh (BITE), Eating Attitudes Test (EAT), Binge Eating Scale (BES) and The Stunkard´s Figure Rating Scale, besides weight measure, height and BMI calculation of the patients. There were verified associations or statistical differences through tests of Chi-Square and T-student and Logistical Regression to identify the factors that influenced the risk of the disease. Results: A total of 58,7% patients presented positive score in tests used for ED risk. There was a significant difference among the groups with and without risk for ED in relation to the BMI (p=0,009), gender (p=0,001), omission of insulin (p=0,003), usage of NPH insulin (p=0,006), lack of usage of Glargine insulin (p=0,021), lack of usage of the technique of carbohydrate counting (p=0,019), blood glucose control (p=0,049) and body dissatisfaction (p=0,001). Conclusion: The suffers of type 1 diabetes presented high frequency of risk behavior for ED, which require more attention when caring for patients for the prevention of the disease.

Introdução - Pacientes portadores de diabetes tipo 1 que manifestam comportamentos de risco para transtornos alimentares (TA) possuem grandes chances de complicações microvasculares e macrovasculares e maiores taxas de mortalidade. Objetivo Avaliar a freqüência de comportamento de risco para TA em adolescentes e adultos portadores de diabetes tipo 1 bem como sua relação com variáveis socioeconômicas, nutricionais, relacionadas ao diabetes e satisfação corporal. Metodologia: Foram aplicados: Teste de Investigação Bulímica de Edinburgh (BITE), Teste de Atitudes Alimentares (EAT), Escala de Compulsão Alimentar Periódica (ECAP) e Escala de Silhuetas de Stunkard, além da mensuração de peso, estatura e cálculo do IMC. Foram verificadas associações ou diferenças estatísticas por meio dos testes de Qui-Quadrado e T-Student e Regressão Logística para identificar fatores que influenciaram o risco da doença. Resultados: Um total de 58,7% dos pacientes apresentaram escore positivo em algum dos testes utilizados para risco de TA. Houve diferença significante entre os grupos com e sem risco para TA com relação ao IMC (p=0,009), gênero (p=0,001), omissão de insulina (p=0,003), uso de insulina NPH (p=0,006), ausência do uso da insulina Glargina (p=0,021), ausência do uso da técnica de contagem de carboidratos (p=0,019), controle da glicemia (p=0,049) e insatisfação corporal (p=0,001). Conclusão: Portadores de diabetes tipo 1 apresentaram grande freqüência de comportamentos de risco para o TA, o que requer atenção e cautela dos profissionais de saúde. / Introduction - Patients suffers of type 1 diabetes that reveal risk behavior for eating disorders (ED) have more chances of micro and macro vascular complications and a high mortality level. Objective Evaluate the frequency of risk behavior for ED in teenagers and adults suffers of type 1 diabetes as well as its relation to the socially economical variable, nutritional variable, related to diabetes and body satisfaction. Methodology: There was applied: The Bulimic Inventory Test of Edinburgh (BITE), Eating Attitudes Test (EAT), Binge Eating Scale (BES) and The Stunkard´s Figure Rating Scale, besides weight measure, height and BMI calculation of the patients. There were verified associations or statistical differences through tests of Chi-Square and T-student and Logistical Regression to identify the factors that influenced the risk of the disease. Results: A total of 58,7% patients presented positive score in tests used for ED risk. There was a significant difference among the groups with and without risk for ED in relation to the BMI (p=0,009), gender (p=0,001), omission of insulin (p=0,003), usage of NPH insulin (p=0,006), lack of usage of Glargine insulin (p=0,021), lack of usage of the technique of carbohydrate counting (p=0,019), blood glucose control (p=0,049) and body dissatisfaction (p=0,001). Conclusion: The suffers of type 1 diabetes presented high frequency of risk behavior for ED, which require more attention when caring for patients for the prevention of the disease.

Background: Type 1 diabetes mellitus is a multifactorial disease caused by beta cell destruction of Langerhans pancreatic islets. From the genetic aspect the main predisposition lays on HLA class II genes (40 - 50%), molecules of which present exogenous peptides to CD4+ T lymphocytes. Enviromental factors play a crucial role in the etiopathogenesis of T1DM. Through epigenetic regulation (e.g. DNA methylation) the genetic and enviromental factors communicate. The level of methylation in the regulatory regions can significantly affect expression of these genes. Aims: The aim of the diploma thesis was to define methylation profile of HLA DQB1 alleles in type 1 diabetes mellitus patients and determine their expression. Methods: The genotyping of HLA class II genes (HLA-DRB1, HLA-DQA1, HLA-DQB1) was performed using sequence specific primers. DNA was treated with sodium bisulfite, regulatory region of HLA DQB1 was amplified and cloned into E.coli, strain DH5α/XL1-Blue. Positive clones were sent for sequencing and results analyzed. RNA was transcribed to cDNA by reverse transcription and the level of expression was analyzed by quantitative PCR. Results: Statistically significant differences were found in total methylation of DQB1*0201 and *0302 alleles in the B section of DQB1 gene. Difference in...

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2005. / Härtill 5 uppsatser.

A retinopatia diabética (RD) é uma complicação microvascular do diabetes melito, sendo a principal causa de cegueira adquirida. Fatores angiogênicos como o vascular endothelial growth factor (VEGF) estão envolvidos na patogênese da RD. O VEGF-A é uma citocina potente e multifuncional que atua através dos receptores VEGFR-1 e VEGFR-2 expressados no endotélio vascular causando aumento da permeabilidade vascular e estímulo à neovascularização em processos fisiológicos e patológicos. A expressão do VEGFR-1 é acentuada por hipóxia e, apesar da afinidade, apresenta fraca resposta ao VEGF enquanto o VEGFR-2 é o principal mediador mitogênico, angiogênico e do aumento da permeabilidade vascular. Alguns polimorfismos do VEGF têm sido estudados na suscetibilidade e risco de progressão da RD. Importante associação entre o polimorfismo -634C/G e a presença de RD é relatada principalmente em relação ao alelo C. A homozigose CC estaria relacionada à RDP e níveis sérico e vítreo aumentados de VEGF sugerindo que a presença do alelo C seja um fator de risco independente para RD. Os conhecimentos sobre o VEGF levaram ao desenvolvimento de agentes anti-VEGF (pegaptanibe, ranibizumabe e bevacizumabe) com objetivo de inibir a neovascularização patológica. A terapia anti-VEGF é uma realidade cujos resultados são cada vez mais promissores na prática médica do tratamento da RD. / Diabetic retinopathy (DR), a DM microvascular complication, is the leading cause of blindness. Angiogenic factors such as vascular endothelial growth factor (VEGF) are involved in the pathogenesis of DR. VEGF-A is a potent, multifunctional cytokine that acts through the receptors VEGFR-1 and VEGFR-2 expressed in the vascular endothelium and causing increased vascular permeability and neovascularization stimulation in both physiological and pathological processes. The expression of VEGFR-1 is upregulated by hypoxia and is less responsive to VEGF compared to VEGFR-2 which is the main mediator mitogenic, angiogenic, and increased vascular permeability. VEGF polymorphisms have been studied in DR susceptibility and progression. Significant association between the polymorphism -634C/G and the presence of DR is reported mainly in relation to allele C. The homozygous CC is associated to proliferative DR and to increased vitreous and serum levels of VEGF suggesting that the presence of the C allele is an independent risk factor for RD. The knowledgement of VEGF lead to the development of anti-VEGF drugs (pegaptanib, ranibizumab and bevacizumab) aiming to prevent pathological neovascularization. The anti-VEGF therapy is a reality in practice medical treatment of DR.

A retinopatia diabética (RD) é uma complicação microvascular do diabetes melito, sendo a principal causa de cegueira adquirida. Fatores angiogênicos como o vascular endothelial growth factor (VEGF) estão envolvidos na patogênese da RD. O VEGF-A é uma citocina potente e multifuncional que atua através dos receptores VEGFR-1 e VEGFR-2 expressados no endotélio vascular causando aumento da permeabilidade vascular e estímulo à neovascularização em processos fisiológicos e patológicos. A expressão do VEGFR-1 é acentuada por hipóxia e, apesar da afinidade, apresenta fraca resposta ao VEGF enquanto o VEGFR-2 é o principal mediador mitogênico, angiogênico e do aumento da permeabilidade vascular. Alguns polimorfismos do VEGF têm sido estudados na suscetibilidade e risco de progressão da RD. Importante associação entre o polimorfismo -634C/G e a presença de RD é relatada principalmente em relação ao alelo C. A homozigose CC estaria relacionada à RDP e níveis sérico e vítreo aumentados de VEGF sugerindo que a presença do alelo C seja um fator de risco independente para RD. Os conhecimentos sobre o VEGF levaram ao desenvolvimento de agentes anti-VEGF (pegaptanibe, ranibizumabe e bevacizumabe) com objetivo de inibir a neovascularização patológica. A terapia anti-VEGF é uma realidade cujos resultados são cada vez mais promissores na prática médica do tratamento da RD. / Diabetic retinopathy (DR), a DM microvascular complication, is the leading cause of blindness. Angiogenic factors such as vascular endothelial growth factor (VEGF) are involved in the pathogenesis of DR. VEGF-A is a potent, multifunctional cytokine that acts through the receptors VEGFR-1 and VEGFR-2 expressed in the vascular endothelium and causing increased vascular permeability and neovascularization stimulation in both physiological and pathological processes. The expression of VEGFR-1 is upregulated by hypoxia and is less responsive to VEGF compared to VEGFR-2 which is the main mediator mitogenic, angiogenic, and increased vascular permeability. VEGF polymorphisms have been studied in DR susceptibility and progression. Significant association between the polymorphism -634C/G and the presence of DR is reported mainly in relation to allele C. The homozygous CC is associated to proliferative DR and to increased vitreous and serum levels of VEGF suggesting that the presence of the C allele is an independent risk factor for RD. The knowledgement of VEGF lead to the development of anti-VEGF drugs (pegaptanib, ranibizumab and bevacizumab) aiming to prevent pathological neovascularization. The anti-VEGF therapy is a reality in practice medical treatment of DR.

A retinopatia diabética (RD) é uma complicação microvascular do diabetes melito, sendo a principal causa de cegueira adquirida. Fatores angiogênicos como o vascular endothelial growth factor (VEGF) estão envolvidos na patogênese da RD. O VEGF-A é uma citocina potente e multifuncional que atua através dos receptores VEGFR-1 e VEGFR-2 expressados no endotélio vascular causando aumento da permeabilidade vascular e estímulo à neovascularização em processos fisiológicos e patológicos. A expressão do VEGFR-1 é acentuada por hipóxia e, apesar da afinidade, apresenta fraca resposta ao VEGF enquanto o VEGFR-2 é o principal mediador mitogênico, angiogênico e do aumento da permeabilidade vascular. Alguns polimorfismos do VEGF têm sido estudados na suscetibilidade e risco de progressão da RD. Importante associação entre o polimorfismo -634C/G e a presença de RD é relatada principalmente em relação ao alelo C. A homozigose CC estaria relacionada à RDP e níveis sérico e vítreo aumentados de VEGF sugerindo que a presença do alelo C seja um fator de risco independente para RD. Os conhecimentos sobre o VEGF levaram ao desenvolvimento de agentes anti-VEGF (pegaptanibe, ranibizumabe e bevacizumabe) com objetivo de inibir a neovascularização patológica. A terapia anti-VEGF é uma realidade cujos resultados são cada vez mais promissores na prática médica do tratamento da RD. / Diabetic retinopathy (DR), a DM microvascular complication, is the leading cause of blindness. Angiogenic factors such as vascular endothelial growth factor (VEGF) are involved in the pathogenesis of DR. VEGF-A is a potent, multifunctional cytokine that acts through the receptors VEGFR-1 and VEGFR-2 expressed in the vascular endothelium and causing increased vascular permeability and neovascularization stimulation in both physiological and pathological processes. The expression of VEGFR-1 is upregulated by hypoxia and is less responsive to VEGF compared to VEGFR-2 which is the main mediator mitogenic, angiogenic, and increased vascular permeability. VEGF polymorphisms have been studied in DR susceptibility and progression. Significant association between the polymorphism -634C/G and the presence of DR is reported mainly in relation to allele C. The homozygous CC is associated to proliferative DR and to increased vitreous and serum levels of VEGF suggesting that the presence of the C allele is an independent risk factor for RD. The knowledgement of VEGF lead to the development of anti-VEGF drugs (pegaptanib, ranibizumab and bevacizumab) aiming to prevent pathological neovascularization. The anti-VEGF therapy is a reality in practice medical treatment of DR.